Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen (NASDAQ:AMGN) has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. Kave Niksefat, senior vice president of Global Marketing and Access, will represent the company at the event scheduled for Wednesday, May 21, 2025, at 9:00 a.m. ET.
The presentation will be accessible via webcast to investors, media, and the general public through Amgen's website (www.amgen.com) under the Investors section. The webcast recording will remain available for replay for a minimum of 90 days following the event.
Amgen (NASDAQ:AMGN) has announced its participation in the upcoming Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2025, at 9:20 a.m. PT. The company will be represented by Peter Griffith, executive vice president and CFO, and Jay Bradner, executive vice president of R&D and chief scientific officer.
The presentation will be accessible through a live webcast on Amgen's website (www.amgen.com) under the Investors section. The webcast recording will remain available for replay for at least 90 days following the event.
Amgen (NASDAQ: AMGN) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, after market close. The company will host a conference call with the investment community at 4:30 p.m. ET.
Key highlights:
- Leadership Participation: Robert A. Bradway, chairman and chief executive officer, along with other senior management team members will lead the discussion
- Public Access: The event will be accessible to news media, investors, and the general public
- Webcast Details: Live audio will be streamed on www.amgen.com under the Investors section
- Replay Availability: The webcast recording will remain accessible for at least 90 days after the event
Interested parties can find additional information about presentation times and webcast links on Amgen's Investor Relations Events Calendar on their website.